

The Congressionally Directed Medical Research Programs FY23 Overview

Presented by
Donna M. Kimbark, Ph.D.
Program Manager, PRCRP

31 March 2023



Transforming Healthcare through Innovative and Impactful Research



CDMRP
DEPARTMENT OF DEFENSE
**CONGRESSIONALLY DIRECTED
MEDICAL RESEARCH PROGRAMS**

The views expressed in this presentation are those of the author and may not reflect the official policy or position of the Department of the Army, Department of Defense, or the U.S. government. Future use of this presentation does not constitute, express, or imply endorsement of the user by the Department of the Army.

UNCLASSIFIED

For more information, visit **cdmrp.health.mil**




Vision

Transform health care through innovative and impactful research



Mission

Responsibly manage collaborative research that discovers, develops, and delivers health care solutions for Service Members, Veterans and the American public



<https://cdmrp.health.mil>

Background: Peer Reviewed Cancer Research Program

News & Highlights

Department of Defense Peer Reviewed Cancer Research Program Funding Opportunities for Fiscal Year 2023 (FY23)

'Hard To Lose' Mutations In Tumors Predict Response To Immunotherapy (external link)

Novel CAR-T Therapy Targeting BAFF-R Against B-Cell Lymphomas

In Her Own Words: Melinda Bachini Speaks about Her Journey with a Rare Cancer and Her Experiences with Living Life to the Fullest

A Promising Nanotech Approach to Enhance Immunotherapy in Liver Cancer

Peer Reviewed Cancer

Vision – To advance mission readiness of U.S. military members affected by cancer and to improve quality of life by decreasing the burden of cancer on Service members, their families, Veterans, and the American public

Since Fiscal Year 2009, the Peer Reviewed Cancer Research Program (PRCRP) has been charged by U.S. Congress to fund innovative basic, applied, and translational cancer research to support Service members, their families, and the American public. Members of the military are exposed to hazardous environments due to the nature of their service and deployments and, thus, are at risk for the development of many types of cancers. The mission of the PRCRP is to successfully promote high-impact research for cancer prevention, detection, treatment, and survivorship. To accomplish this task, the PRCRP seeks to fund different areas of the research landscape. Funding innovative and translational research the PRCRP offers funding opportunities directed toward the special focus of Service members and potential cancer risks; focusing on the gaps in cancer research with respect to unique situations and military environments. Additionally, the PRCRP addresses growing and developing the future in research through targeted funding opportunities for early career investigators. With a funding program focused on military health and welfare in cancer research, the PRCRP strives to improve the quality of life by decreasing the impact of cancer on Service members, their families and the American public by funding highly relevant and innovative research.

Peer Reviewed Cancer Research Program Overarching Challenges



[Click on Image to View Program Booklet](#)



[Click on Image to View Strategic Plan](#)

Began in Fiscal Year (FY) 2009 with an appropriation of \$16 Million (M) and congressional language directing the topic areas (specific cancers and other research areas) to be funded. From FY09-FY22, a total of 36 topic areas have been included under the PRCRP.

- FY09-FY22: \$784.8 M, 921 awards
- FY23: \$130 M, To be determined

▪ **Vision** – To advance mission readiness of those U.S. military members affected by cancer; and to improve quality of life by decreasing the burden of cancer on Service Members, their families, Veterans, and the American public.

▪ **Mission** – To successfully promote high-impact cancer research for prevention, detection, treatment, quality of life, and survivorship.

cdmrp.health.mil/prcrp

FY23 Topic Areas for Peer Reviewed Cancer Research Program

- Bladder Cancer
- Blood Cancer
- Brain Cancer
- Colorectal Cancer
- Endometrial Cancer
- Esophageal Cancer
- Germ Cell Cancers
- Head and Neck Cancer
- Liver Cancer
- Lymphoma
- Mesothelioma
- Metastatic Cancer
- Myeloma
- Neuroblastoma
- Pediatric, Adolescent and Young Adult Cancers
- Pediatric Brain Tumors
- Sarcoma
- Stomach Cancer
- Thyroid Cancer
- Von Hippel-Lindau Syndrome Malignancies (excluding cancers of the kidney and pancreas)

Applicants must address at least one of the Topic Areas, as directed by Congress

Funds may not be used for research into breast, kidney, lung, ovarian, pancreatic, prostate, rare cancers, or melanoma




Research must be relevant to Service Members, their Families, Veterans, and other military beneficiaries

*The inclusion of the individual Rare Cancers Research Program **shall not** prohibit the PRCRP from funding the above-mentioned cancers or cancer subtypes that may be rare by definition*

Impact of Cancer on Military Health

Cancer Risk Factors	Mission Readiness
Traumatic brain injury increases hazard ratio for development of brain cancer	Cancer diagnoses in Service Members and their families lead to force vulnerabilities
Environmental exposures such as asbestos leads to mesothelioma risk	Gaps in our knowledge of cancer care cause gaps in mission readiness
Exposures to ionizing radiation leads to uterine, thyroid, blood, and other cancers	Cancer affects the whole unit's readiness , not just a single Service Member
Infectious diseases such as H. pylori is associated with stomach cancer risk	Military Health Systems are burdened with healthcare costs due to cancer diagnoses and treatment

Requirement for all applicants to respond to Military Health Focus Areas




FY23 PRCRP: Topic Areas and Portfolios

General Oncology*



Bladder Cancer
Mesothelioma
Metastatic
Cancers

Hematology



Blood Cancers
Lymphoma
Myeloma

Neurology



Brain Cancer
Pediatric Brain
Tumors

Otolaryngology



Head and Neck
Cancers

Pediatric



Pediatric,
Adolescent and
Young Adult
Sarcoma
Thyroid Cancer
Neuroblastoma

Reproductive Hereditary



Endometrial
Cancer
Germ Cell
Cancers
VHL
malignancies

Gastroenterology



Esophageal
Cancer
Colorectal
Cancer
Liver cancer
Stomach Cancer

*Portfolio are not directed by Congress and are used for management purposes only. Other Portfolios such as Legacy Portfolios cover topic areas no longer included under PRCRP.

FY23 PRCRP Cancer Capability Gaps Overarching Challenges

Prevention




- *Develop innovative prevention strategies and early detection methods to decrease cancer burden
- *Elucidate the mechanisms underlying cancer development to improve prevention methods

Diagnostics



- *Identify strategies to predict treatment resistance, recurrence, and the development of advanced disease.
- *Distinguish unique features driving cancer occurrence across the spectrum of ages.
- *Develop and improve minimally invasive methods to detect cancer initiation, progression, and recurrence

Treatment



- *Transform cancer treatment, especially for advanced disease and metastasis
- *Improve current therapies including systemic and local treatments.
- *Longitudinal evaluation of disease progression and/or treatment response.
- *Elucidate the mechanisms of cancer development to improve treatment methods

FY23 PRCRP Cancer Capability Gaps Overarching Challenges - Continued

Patient Well-Being and Survivorship



- *Develop strategies to address survivorship issues including quality of life, overall mental health, psychological impact of recurrence, and/or survivor permanent disability
- *Develop strategies to reduce short- and long-term treatment effects, including neurocognitive deficits.
- *Bridge gaps between treatment and survivorship including alternative medicine, nutrition and lifestyle factors, and supportive care

Disparity



- *Improve prevention strategies, diagnosis, treatment, and outcomes for patients in underserved or under recognized populations
- *Develop strategies to improve accessibility to care and to address survivorship.
- *Advance health equity and reduce disparities in cancer care through research.

Resources



- *Develop open access platform(s) or methods/tools to coordinate and integrate multiple databases, biorepositories, and data-sharing interfaces
- *Facilitate longitudinal collection of clinically annotated biospecimens and analysis of these specimens to further improve patient outcomes
- *Develop technologies for machine learning and artificial intelligence to improve patient quality of life, survivorship, and outcomes

PRCRP: Esophageal Facts and Funding


General Military Health Facts*

- ◆ VA allows Veterans to collect benefits for esophageal cancer due to Agent Orange and other related pesticides exposures.
- ◆ Link to cancers such as esophageal cancer to contamination of water at Camp Lejeune
- ◆ Esophageal cancer linked to exposures to various chemicals including trichloroethylene and tetrachloroethylene


Funding: FY20-FY22

Topic Area	#Awards	Investment
Esophageal Cancer	13	\$13.7M

FY20-21 PRCRP Portfolio (% Research Dollars)




National Toxicology Program (NTP). Report on carcinogens. 14th edition. 2016. Mundt KA, Birk T, Burch MT. 2003. Int Arch Occup Environ Health. 76:473-91.
 Paulu C, Aschengrau A, Ozonoff D. 1999. Environ Health Perspect 107(4):265-71






- **Initiative I: Advance Convergent Science in Cancer Research**
 - Convergent Science Virtual Cancer Center to catalyze training of early career investigators in an interactive multi-cancer network.
 - Cultivate convergent science to advance cancer research through innovative funding opportunities.
- **Initiative II: Support the Research Continuum toward Fielded Science**
 - Support innovative, discovery-based research.
 - Enhance translational research.
 - Accelerate research toward fielded science.

Initiative II: Support the Research Spectrum FY23 Investment Strategy

- ✓ Choose the right funding opportunity
- ✓ Not all funding opportunities are alike



FY23 PRCRP Funding Opportunities

Mechanism	Key Characteristics	Funding (Direct Costs)	Deadline Dates
Advancing Cancer Care through Clinical Trials Award (ACCCT)	<ul style="list-style-type: none"> • Pre-application screened for invitation • Supporting a clinical trial with focus on cancer care • Preliminary data required • Transition to next phase of development 	\$3M over 4 years	Preapp: 25 May 2023 Full App: 12 Sept 2023 
Career Development Award- Fellow Option	<ul style="list-style-type: none"> • Letter of Intent: No invitation needed • Eligibility: Research Assistant Professor, instructor. • Early career investigators not fully independent. • Intended to support the wider independence 	\$400K over 2 years	Letter of Intent (LOI): 25 July 2023 Full App: 10 Aug 2023
Career Development Award – Resident Option	<ul style="list-style-type: none"> • Letter of Intent: No invitation needed • Eligibility: Physician Scientist in Residency. • Research Funding levels for 1 year or 2 years • Protected time required 	\$200K over 1 year \$400K over 2 years	LOI: 3 Aug 2023 Full App: 24 Aug 2023
Idea Award	<ul style="list-style-type: none"> • Pre-application screened for invitation • High risk/high gain, innovation is key! • Preliminary data discouraged 	\$400K over 2 years	Preapp: 25 May 2023 Full App: 12 Sept 2023 
Impact Award	<ul style="list-style-type: none"> • Pre-application screened for invitation • Supports research toward clinical applicability • Clinical trials allowed • Preliminary data required 	\$1M over 3 years	Preapp: 25 May 2023 Full App: 12 Sept 2023 
Patient Well-Being and Survivorship Award	<ul style="list-style-type: none"> • Letter of Intent: No invitation needed • Formerly Behavior Health Science Award • Studies focusing on survivorship and Quality of Life • Allows pilot clinical trials 	\$1M over 3 years	LOI: 25 July 2023 Full App: 10 Aug 2023
Translational Team Science Award	<ul style="list-style-type: none"> • Letter of Intent: No invitation needed • Supports 2-3 Principal Investigators • Correlative studies associated with a clinical trial • Preliminary data required 	\$2.5M over 4 years	LOI: 25 July 2023 Full App: 10 Aug 2023

Invitation Required Opportunities

Idea Award

- One-page pre-proposal
- *Preliminary data is discouraged!*
- Basic, high risk/high gain research
- Independent PIs
- \$400k over 2 years

Impact Award

- One-page pre-proposal
- Clinical trial option
- *Preliminary data is required*
- Continuity of research with emphasis on near term impact
- Assistant Professor or equivalent
- \$1M over 3 years

Advancing Cancer Care through Clinical Trials (ACCCTA)

- Three-page pre-proposal
- *Pre-clinical data is required*
- Clinical trial is required
- No preclinical projects allowed
- IND/IDE submission by time of application deadline
- Assistant Professor or equivalent
- \$3M over 4 years

Idea and Impact Awards: Pre-proposal due 25 May 2023
Invitation by 29 June 2023
Full application due 12 September 2023

ACCCTA: Pre-proposal due 25 May 2023
Invitation by 29 June 2023
Full application due 27 September 2023

Letter of Intent Opportunities

Patient Well-Being and Survivorship Award

- Letter of Intent: Pilot Clinical Trial (PCT) Option - Preliminary data only required for PCT Option
- Independent Investigator
- Quality of life, preservation of function, neurocognitive issues, long term side effects
- \$1 M over 3 years

Translational Team Science Award

- Letter of Intent: Clinical Trial Option
- Preliminary data required for supporting correlative studies associated with ongoing or completed clinical trial
- At least 2-3 PIs at the level of Assistant Professor
- \$2.5 M for 4 years

Career Development Award –Fellow Option

- Letter of Intent: For scientists or Physician Scientists within 7 years of terminal degree
- Preliminary data not required
- Supports early career investigators toward further independence
- Research Assistant Professor, Instructor – independent lab space is not required
- \$400k over 3 years

Career Development Award – Resident Option


- Letter of Intent: For Residents to participate in research
- Preliminary data not required
- Supports two different research levels-required to perform work between June 2024-2026
- Research level 1: \$200K over 1 year or Research Level 2: \$400K over 2 years

Letter of Intent due 25 July 2023


Full application due 10 August 2023

Funding Opportunities

- Pre-announcements and funding opportunity release notifications
 - CDMRP website and email blasts
- Funding opportunity postings
 - Grants.gov (CFDA 12.420)
 - CDMRP website (cdmrp.health.mil)
 - electronic Biomedical Research Application Portal (eBRAP) system (ebrap.org)
- Quickly find open CDMRP Funding Opportunities on the CDMRP website here:
 - Home > Funding Opportunities > Synopsis of Open Program Funding Opportunities




Understanding the *goals of the program, intent of the award mechanism, and review criteria* is critical for a successful application



- The funding opportunity announcement contains information on:
 - Program Goals
 - Focus Areas/Topics
 - Award Intent
 - Required Elements, Eligibility, and Funding
 - Review Criteria
 - Deadlines

Single most important tip:
Read the announcement carefully

Program Cycle



Goal of the Two-Tier Review Process

To develop funding recommendations that balance *the most meritorious science* across many disciplines and offer the highest promise to *fulfill the programmatic goals* set forth in the funding opportunity

Peer Review

- Criterion-based evaluation of full proposal
- Determination of “absolute” scientific merit
- **Outcome: Summary Statements**
 - No standing panels; reviewers are recruited based on expertise needed
 - No contact between applicants, reviewers, and program staff

Partnership



Programmatic Review

- Comparison among proposals of high scientific merit
- Determination of adherence to intent, program relevance, and potential for impact
- **Outcome: Funding Recommendations**
 - No “pay line” (portfolio balance)
 - Funds obligated up-front; limited out-year budget commitments (but milestones imposed)
 - No continuation funding



Video and additional information available at: <https://cdmrp.health.mil/about/2tierRevProcess>

(PRCRP verbiage example)


II.E.1.a. Peer Review

To determine technical merit, all applications will be evaluated according to the following **scored criteria**, which are listed in decreasing order of importance:

Example Peer Review Criteria	
Scored	Unscored
Principal Investigator	Personnel
Career Development Plan, Environment, Career Guide	Budget
Research Strategy and Feasibility	Application Presentation
Impact	

- **Principal Investigator**

- Whether the PI meets the eligibility requirements.
- To what degree the PI's career goals demonstrate a strong personal commitment to advancing an independent career at the forefront of cancer research.
- How relevant the research would be to support the early-career investigator toward wider independence and success.
- To what extent the PI's record of accomplishments and letters of support demonstrate their potential for advancement as a productive, independent investigator in cancer research in at least one of the FY23 PRCRP Topic Areas in [Section II.A.1](#) and at least one of the [FY23 PRCRP Overarching Challenges](#).
- Whether the application demonstrates that the candidate has been named on and awarded nominal career development funding.



Programmatic Review Criteria

(PRCRP verbiage example)

II.E.1.b. Programmatic Review

To make funding recommendations and select the application(s) that, individually or collectively, will best achieve the program objectives, the following criteria are used by programmatic reviewers:

- Ratings and evaluations of the peer reviewers
- Relevance to the mission of the DHP and FY23 PRCRP, as evidenced by the following:

Fellow and Resident Options:

- Adherence to the intent of the award mechanism
- Program portfolio composition
- Programmatic relevance to the FY23 Military Health Focus Areas
- Programmatic relevance to the FY23 PRCRP Overarching Challenges
- Relative impact |

Programmatic Panel
membership lists are
available on the
CDMRP website



Strategies to Answer Challenges

● Plan Ahead

- ◆ Deadlines are important!
- ◆ Dissect the Funding Opportunity and Understand it
- ◆ Coordinate your efforts: bring the team together early

● Grantsmanship

- ◆ Clear voice, forget the jargon: don't tire the reviewers
- ◆ Review your documents prior to submission: use the verification period!
- ◆ Use the Peer Review Criteria as your check list!

● What's the Intent

- ◆ The Ted Talk: state your idea upfront, then back it up!
- ◆ Make your case to how your research aligns with the intent


● Impact

- ◆ Cool science is good: **Impactful science is great!**
- ◆ Show how it is impactful, important to patients
- ◆ Use plain language! You will be evaluated on this!

● Feasibility

- ◆ Clearly define your team's skills
- ◆ Outline your justification on how and why you can achieve the anticipated outcomes

Questions? help@eBRAP.org






Pitfalls to Avoid in Application Submission

- **Do not** include Programmatic Panel members for the program and fiscal year to which you are applying
- **Do not** exceed the page limits; check files after creating PDF version
- **Do not** miss the submission deadline
 - Grants.gov validation may take up to 72 hours
 - System-to-system submissions are sometimes problematic
 - Application verification in eBRAP is possible before the deadline
- **Do NOT ignore the Verification Period!**
- **Submit the correct Project Narrative and Budget**
 - These components **cannot be modified** during the verification period in eBRAP

FY23 Panel Member Organization
Lt. Col. Della Howell, M.D., U.S. Air Force Retired (Chair) Methodist Children's Hospital
Jill Barnholtz-Sloan, Ph.D. National Cancer Institute
Clark Chen, M.D., Ph.D. University of Minnesota
Cmdr. Michele Gage, M.D., U.S. Navy Walter Reed National Military Medical Center
Doug Hawkins, M.D. Seattle Children's Hospital
Adam Hayden, (Consumer) National Brain Tumor Society
Yin-Fen Lee, Ph.D. University of Rochester
Barbara Lind (Consumer) Society of Gemological Oncology
Aaron Mansfield, M.D. The Mayo Clinic
Robert Mesloh (Consumer) Lymphoma Research Foundatio
Col. Thomas Newton, M.D., U.S. Air Force Retired Inova Schar Cancer Institute
Col. Aaron Pitney, M.D., U.S. Army U. S. Army Training and Doctrine Command
Heath Skinner, M.D., Ph.D. University of Pittsburgh
Kenneth Tanabe, M.D. Massachusetts General Hospital

23

FY23 PRCRP Funding Opportunities

Mechanism	Key Characteristics	Deadline Dates
Advancing Cancer Care through Clinical Trials Award (ACCCT)	<ul style="list-style-type: none"> Pre-application screened for invitation \$3M over 4 years 	Preapp: 25 May 2023 Full App: 12 Sept 2023
Career Development Award- Fellow Option	<ul style="list-style-type: none"> Letter of Intent: No invitation needed \$400K over 2 years 	Letter of Intent (LOI): 25 July 2023 Full App: 10 Aug 2023
Career Development Award – Resident Option	<ul style="list-style-type: none"> Letter of Intent: No invitation needed Research Level 1: \$200K over 1 year Research Level 2: \$400K over 2 years 	LOI: 3 Aug 2023 Full App: 24 Aug 2023
Idea Award	<ul style="list-style-type: none"> Pre-application screened for invitation \$400 over 2 years 	Preapp: 25 May 2023 Full App: 12 Sept 2023
Impact Award	<ul style="list-style-type: none"> Pre-application screened for invitation \$1M over 3 years 	Preapp: 25 May 2023 Full App: 12 Sept 2023
Patient Well-Being and Survivorship Award	<ul style="list-style-type: none"> Letter of Intent: No invitation needed \$1M over 3 years 	LOI: 25 July 2023 Full App: 10 Aug 2023
Translational Team Science Award	<ul style="list-style-type: none"> Letter of Intent: No invitation needed \$2.5M over 4 Years 	LOI: 25 July 2023 Full App: 10 Aug 2023

Questions?

For more information, please visit:



cdmrp.health.mil



CDMRP

DEPARTMENT OF DEFENSE

**CONGRESSIONALLY DIRECTED
MEDICAL RESEARCH PROGRAMS**